{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:20:15Z","timestamp":1771266015683,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,2,12]],"date-time":"2009-02-12T00:00:00Z","timestamp":1234396800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s10549-009-0332-2","type":"journal-article","created":{"date-parts":[[2009,2,11]],"date-time":"2009-02-11T12:03:26Z","timestamp":1234353806000},"page":"603-609","source":"Crossref","is-referenced-by-count":71,"title":["Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC"],"prefix":"10.1007","volume":"117","author":[{"given":"Stephanie L.","family":"Hines","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betty","family":"Mincey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todor","family":"Dentchev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff A.","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith A.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul L.","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Alberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heshan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Kahanic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslaw A.","family":"Mazurczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Nikcevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles L.","family":"Loprinzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,2,12]]},"reference":[{"issue":"9","key":"332_CR1","first-page":"1029","volume":"20","author":"EA Perez","year":"2006","unstructured":"Perez EA, Weilbaecher K (2006) Aromatase inhibitors and bone loss. Oncology 20(9):1029\u20131039","journal-title":"Oncology"},{"issue":"1","key":"332_CR2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","volume":"14","author":"T Powles","year":"1996","unstructured":"Powles T, Hickish T, Kanis JA, Tidy A, Ashley S (1996) Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14(1):78\u201384","journal-title":"J Clin Oncol"},{"issue":"9","key":"332_CR3","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/cncr.11745","volume":"98","author":"The ATAC Trialists\u2019 Group","year":"2003","unstructured":"The ATAC Trialists\u2019 Group (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer 98(9):1802\u20131810. doi: 10.1002\/cncr.11745","journal-title":"Cancer"},{"key":"332_CR4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","volume":"365","author":"The ATAC Trialists\u2019 Group","year":"2005","unstructured":"The ATAC Trialists\u2019 Group (2005) Results of the ATAC trial after completion of 5\u00a0years\u2019 adjuvant treatment for breast cancer. Lancet 365:60\u201362. doi: 10.1016\/S0140-6736(04)17666-6","journal-title":"Lancet"},{"issue":"19","key":"332_CR5","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","volume":"349","author":"PE Goss","year":"2003","unstructured":"Goss PE, Ingle JN, Martino S, Robert JN, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19):1793\u20131802. doi: 10.1056\/NEJMoa032312","journal-title":"N Engl J Med"},{"issue":"11","key":"332_CR6","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"RC Coombes","year":"2004","unstructured":"Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350(11):1081\u20131092. doi: 10.1056\/NEJMoa040331","journal-title":"N Engl J Med"},{"issue":"5","key":"332_CR7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","volume":"25","author":"AS Coates","year":"2007","unstructured":"Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret MJ, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG1\u201398. J Clin Oncol 25(5):486\u2013491. doi: 10.1200\/JCO.2006.08.8617","journal-title":"J Clin Oncol"},{"issue":"26","key":"332_CR8","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","volume":"353","author":"The Breast International Group (BIG) 1\u201398 Collaboratie Group","year":"2005","unstructured":"The Breast International Group (BIG) 1\u201398 Collaboratie Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353(26):2747\u20132757. doi: 10.1056\/NEJMoa052258","journal-title":"N Engl J Med"},{"issue":"8","key":"332_CR9","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","volume":"21","author":"R Eastell","year":"2006","unstructured":"Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE (2006) Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination trial. J Bone Miner Res 21(8):1215\u20131223. doi: 10.1359\/jbmr.060508","journal-title":"J Bone Miner Res"},{"issue":"22","key":"332_CR10","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","volume":"24","author":"EA Perez","year":"2006","unstructured":"Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA. 17. J Clin Oncol 24(22):3629\u20133635. doi: 10.1200\/JCO.2005.05.4882","journal-title":"J Clin Oncol"},{"issue":"9","key":"332_CR11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Meunier PJ (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346(9):653\u2013661. doi: 10.1056\/NEJMoa011807","journal-title":"N Engl J Med"},{"issue":"7","key":"332_CR12","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","volume":"25","author":"A Brufsky","year":"2007","unstructured":"Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25(7):829\u2013836. doi: 10.1200\/JCO.2005.05.3744","journal-title":"J Clin Oncol"},{"key":"332_CR13","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1359\/JBMR.050304","volume":"20","author":"O Johnell","year":"2005","unstructured":"Johnell O, Kanis JA, Oden A et al (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185\u20131194. doi: 10.1359\/JBMR.050304","journal-title":"J Bone Miner Res"},{"issue":"18","key":"332_CR14","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Chung Leung P, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue T, Sellmeyer D, Fink Eriksen E, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809\u20131822. doi: 10.1056\/NEJMoa067312","journal-title":"N Engl J Med"},{"issue":"24","key":"332_CR15","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280(24):2077\u20132082. doi: 10.1001\/jama.280.24.2077","journal-title":"JAMA"},{"key":"332_CR16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00223-003-0042-4","volume":"74","author":"JT Harrington","year":"2004","unstructured":"Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, Barton I, Boonen S (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129\u2013135. doi: 10.1007\/s00223-003-0042-4","journal-title":"Calcif Tissue Int"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-009-0332-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-009-0332-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-009-0332-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:32:15Z","timestamp":1559233935000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-009-0332-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,12]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["332"],"URL":"https:\/\/doi.org\/10.1007\/s10549-009-0332-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,12]]}}}